JP2018530568A5 - - Google Patents

Download PDF

Info

Publication number
JP2018530568A5
JP2018530568A5 JP2018517898A JP2018517898A JP2018530568A5 JP 2018530568 A5 JP2018530568 A5 JP 2018530568A5 JP 2018517898 A JP2018517898 A JP 2018517898A JP 2018517898 A JP2018517898 A JP 2018517898A JP 2018530568 A5 JP2018530568 A5 JP 2018530568A5
Authority
JP
Japan
Prior art keywords
cancer
agonist
composition
acting
long
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018517898A
Other languages
English (en)
Japanese (ja)
Other versions
JP7407511B2 (ja
JP2018530568A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/056088 external-priority patent/WO2017062832A1/en
Publication of JP2018530568A publication Critical patent/JP2018530568A/ja
Publication of JP2018530568A5 publication Critical patent/JP2018530568A5/ja
Application granted granted Critical
Publication of JP7407511B2 publication Critical patent/JP7407511B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018517898A 2015-10-08 2016-10-07 ＩＬ－２Ｒβ選択的作動薬と長時間作用型ＩＬ－１５作動薬との併用 Active JP7407511B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562239207P 2015-10-08 2015-10-08
US62/239,207 2015-10-08
PCT/US2016/056088 WO2017062832A1 (en) 2015-10-08 2016-10-07 Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021016606A Division JP2021066748A (ja) 2015-10-08 2021-02-04 ＩＬ−２Ｒβ選択的作動薬と長時間作用型ＩＬ−１５作動薬との併用

Publications (3)

Publication Number Publication Date
JP2018530568A JP2018530568A (ja) 2018-10-18
JP2018530568A5 true JP2018530568A5 (enExample) 2019-11-14
JP7407511B2 JP7407511B2 (ja) 2024-01-04

Family

ID=57249859

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018517898A Active JP7407511B2 (ja) 2015-10-08 2016-10-07 ＩＬ－２Ｒβ選択的作動薬と長時間作用型ＩＬ－１５作動薬との併用
JP2021016606A Withdrawn JP2021066748A (ja) 2015-10-08 2021-02-04 ＩＬ−２Ｒβ選択的作動薬と長時間作用型ＩＬ−１５作動薬との併用
JP2023085387A Withdrawn JP2023099731A (ja) 2015-10-08 2023-05-24 ＩＬ－２Ｒβ選択的作動薬と長時間作用型ＩＬ－１５作動薬との併用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021016606A Withdrawn JP2021066748A (ja) 2015-10-08 2021-02-04 ＩＬ−２Ｒβ選択的作動薬と長時間作用型ＩＬ−１５作動薬との併用
JP2023085387A Withdrawn JP2023099731A (ja) 2015-10-08 2023-05-24 ＩＬ－２Ｒβ選択的作動薬と長時間作用型ＩＬ－１５作動薬との併用

Country Status (10)

Country Link
US (1) US12233104B2 (enExample)
EP (1) EP3359182B1 (enExample)
JP (3) JP7407511B2 (enExample)
KR (1) KR102861230B1 (enExample)
CN (1) CN108135978A (enExample)
AU (1) AU2016335860B2 (enExample)
IL (1) IL258456B (enExample)
MA (1) MA47290A (enExample)
MX (1) MX2018004296A (enExample)
WO (1) WO2017062832A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111093688B (zh) * 2017-05-15 2025-09-16 尼克塔治疗公司 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法
US11248025B2 (en) 2019-06-03 2022-02-15 Medikine, Inc. IL-2alpha receptor subunit binding compounds
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401756A (en) 1981-04-14 1983-08-30 Immunex Corporation Process for preparing human interleukin 2
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
DE3676670D1 (de) 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4705848A (en) 1986-06-02 1987-11-10 International Minerals & Chemical Corp. Isolation of bioactive, monomeric growth hormone
US5078997A (en) 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5153310A (en) 1989-02-28 1992-10-06 Du Pont Merck Pharmaceutical Company Il-2 analogs containing n-linked glycosylation sites
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US6077519A (en) * 1993-01-29 2000-06-20 University Of Pittsburgh Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
ATE293168T1 (de) * 1993-11-12 2005-04-15 Gilead Sciences Inc Thrombin mutanten
US5635597A (en) 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US7008624B1 (en) 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
US6034072A (en) 1997-02-10 2000-03-07 Genemedicine, Inc. IL-2 gene expression and delivery systems and uses
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6362254B2 (en) 1998-03-12 2002-03-26 Shearwater Corporation Poly(ethylene glycol) derivatives with proximal reactive groups
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
DE60138222D1 (de) 2000-09-14 2009-05-14 Beth Israel Hospital Modulierung von il-2 und il-15 vermittelten t zellantworten
AU2000202A (en) 2000-10-31 2002-05-15 Pr Pharmaceuticals Inc Methods and compositions for enhanced delivery of bioactive molecules
FR2826365B1 (fr) 2001-06-20 2003-09-26 Oreal Compositions cosmetiques photoprotectrices contenant des derives amides, sulfonamides ou carbamates aromatiques d'acrylonitrile et nouveaux derives amides, sulfonamides ou carbamates d'acrylonitrile
KR100974843B1 (ko) 2002-09-09 2010-08-11 넥타르 테라퓨틱스 수용성 중합체 알카날
AU2003303636B2 (en) 2002-12-26 2010-08-05 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
JP4490290B2 (ja) 2002-12-31 2010-06-23 ネクター セラピューティクス アラバマ，コーポレイション 加水分解安定性マレイミド末端ポリマー
AU2004204136B2 (en) 2003-01-06 2008-10-09 Nektar Therapeutics Thiol-selective water-soluble polmer derivatives
CA2521784C (en) 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
ES2725808T3 (es) 2003-05-23 2019-09-27 Nektar Therapeutics Derivados de PEG que contienen dos cadenas de PEG
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
JP2007506789A (ja) 2003-09-25 2007-03-22 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２１を用いた自己免疫疾患の治療方法
AU2004298996A1 (en) 2003-12-10 2005-06-30 Nektar Therapeutics Al, Corporation Compositions comprising two different populations of polymer-active agent conjugates
WO2006017853A2 (en) 2004-08-11 2006-02-16 Beth Israel Deaconess Medical Center, Inc. Mutant interleukin-15-containing compositions and suppression of an immune response
JP2008515896A (ja) 2004-10-05 2008-05-15 オクスナー クリニック ファウンデーション Ｉｌ−１５によるｂ細胞増殖の増強
PL1688146T3 (pl) 2005-02-07 2007-12-31 Novartis Vaccines & Diagnostics Inc Przygotowywanie aldesleukiny do zastosowania farmaceutycznego
JP4560629B2 (ja) * 2005-03-31 2010-10-13 国立大学法人 筑波大学 腫瘍壊死誘導療法の抗腫瘍効果増強剤
US20060257361A1 (en) * 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
DK2390267T3 (da) 2005-06-07 2013-08-26 Esbatech A Novartis Co Llc Stabile og opløselige antistoffer, der hæmmer TNF(alfa)
PT2279758E (pt) 2005-06-16 2015-05-27 Nektar Therapeutics Conjugados possuindo uma ligação degradável e reagentes poliméricos úteis na preparação de tais conjugados
EP2364735A3 (en) 2005-12-16 2012-04-11 Nektar Therapeutics Branched PEG conjugates of GLP-1
AU2006328943B2 (en) * 2005-12-21 2011-07-21 Sentoclone International Ab Improved method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer
WO2007117685A2 (en) 2006-04-07 2007-10-18 Nektar Therapeutics Al, Corporation Conjugates of an anti-tnf-alpha antibody
CN101104077A (zh) 2006-07-12 2008-01-16 北京紫辰医药生物技术研究所 重组人白介素-2与聚乙二醇的偶合物
NZ577397A (en) 2006-12-27 2012-01-12 Nektar Therapeutics Factor ix moiety-polymer conjugates having a releasable linkage
MX2009007145A (es) 2006-12-27 2009-08-27 Nektar Therapeutics Al Corp Conjugados de polimero con factor viii y factor de von willebrand que tienen una ligadura liberable.
CN101686687A (zh) 2007-02-28 2010-03-31 塞瑞纳治疗公司 活化的聚噁唑啉及包含该聚噁唑啉的组合物
CA2712224C (en) 2008-02-01 2016-03-08 Ascendis Pharma As Prodrug comprising a drug linker conjugate
KR20090103209A (ko) 2008-03-27 2009-10-01 (주)한국비엠아이 사람 인터루킨-2 동종체
WO2009135031A1 (en) * 2008-04-30 2009-11-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Substituted il-15
CA2723821C (en) 2008-05-16 2017-05-02 Nektar Therapeutics Conjugates of a cholinesterase moiety and a polymer
WO2010014258A2 (en) 2008-08-01 2010-02-04 Nektar Therapeutics Al, Corporation Conjugates having a releasable linkage
EP2898900B1 (en) 2008-09-19 2017-11-15 Nektar Therapeutics Polymer conjugates of ziconotide
WO2010048184A2 (en) 2008-10-21 2010-04-29 Baxter International Inc. Methods for determining active ingredients in pro-drug peg protein conjugates with releasable peg reagents (in vitro de-pegylation)
AU2011282571C1 (en) 2010-07-30 2018-04-05 Takeda Pharmaceutical Company Limited Nucleophilic catalysts for oxime linkage
KR102591732B1 (ko) * 2010-11-12 2023-10-19 넥타르 테라퓨틱스 Ｉｌ-2 부분 및 중합체의 접합체
WO2013020079A2 (en) * 2011-08-04 2013-02-07 Nektar Therapeutics Conjugates of an il-11 moiety and a polymer
US20150017120A1 (en) 2013-06-13 2015-01-15 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
EP3834838A1 (en) * 2014-02-21 2021-06-16 Nektar Therapeutics (India) Pvt. Ltd. Il-2rbeta-selective agonists in combination with an anti-pd-1 antibody
MA39711A (fr) * 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère

Similar Documents

Publication Publication Date Title
Kumari et al. Gold nanoparticles: New routes across old boundaries
JP2019534308A5 (enExample)
US11554178B2 (en) Compositions and methods of modulating macrophage activity
Hiniker et al. Abscopal effect in a patient with melanoma
JP2016533344A5 (enExample)
Jett et al. Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer.
JP2016522261A5 (enExample)
JP2019515908A5 (enExample)
JP2020514300A5 (enExample)
JP2021515083A5 (enExample)
JP2001247459A5 (enExample)
JP2020537501A5 (enExample)
JP2020519676A5 (enExample)
US20200016206A1 (en) Immunotherapeutic tumor treatment method using an interleukin-2 receptor alpha, beta-selective agonist in combination with adoptive cell transfer therapy
Park et al. Personalized combination nano-immunotherapy for robust induction and tumor infiltration of CD8+ T cells
JP2010511713A (ja) 薬物送達
TWI641374B (zh) 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑
AU2021202582B2 (en) Nanoparticles for use as a therapeutic vaccine
JP2007524613A5 (enExample)
JP2019505585A5 (enExample)
JP2021505541A5 (enExample)
JP2022526408A5 (enExample)
JP2012503602A5 (enExample)
JP2020534300A5 (enExample)
York et al. Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma